secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001193125-22-288951
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio receives Nasdaq delisting notice for negative stockholders' equity
-----------------------------------------------------------------------------

- Reported stockholders' equity of ($19,540,000) as of Sept 30, 2022, below Nasdaq's $2.5M minimum.
- Must submit compliance plan by December 30, 2022; if accepted, up to 180 days to regain compliance.
- Stock continues trading on Nasdaq Capital Market pending plan review and potential hearing.
- Company is evaluating options to resolve deficiency; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312522288951/0001193125-22-288951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312522288951/d391567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-288951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer